Actelion at neutral by Merrill

Merrill Lynch analyst Erica Whittaker rated Actelion at neutral after third-quarter results beat the analyst's forecast, due mostly to higher-than-expected Tracleer sales. The company had net revenues of CHF 247.2 million and an operating profit of CHF 76.5 million. Actelion has revised its 2006 outlook to revenues of CHF 930 million to CHF 940 million. Shares of the Allschwil, Switzerland-based pharmaceutical company were up CHF 9.69, or 6.83%, at CHF 151.73. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.